厄洛替尼和埃克替尼是一种选择性表皮生长因子受体(epidermal growth factor receptor,EGFR)——酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI),在进展期非小细胞肺癌(NSCLC)中具有靶向治疗作用。靶向药物治疗一般作为二线或三线用药,其治疗失败后很少有行之有效的治疗策略。本文报道1例晚期NSCLC厄洛替尼治疗失败后采用埃克替尼靶向治疗有效的病例。1资料患者男性,78岁,因痰血2月余于2009年6月30日入 Erlotinib and Icotinib, a selective epidermal growth factor receptor (EGFR) -type tyrosine kinase inhibitor (TKI), play an important role in advanced non-small cell lung cancer (NSCLC) with targeted therapies. Targeted drug therapy is generally used as second-line or third-line drugs, and after treatment fails, few effective treatment strategies. This article reports a case of advanced NSCLC erlotinib failure after treatment with imatinib targeted the effective treatment of cases. 1 data patients male, 78 years old, due to sputum blood more than February 30, 2009 into